S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 210.5 JPY -0.05% Market Closed
Market Cap: 2T JPY
Have any thoughts about
Shionogi & Co Ltd?
Write Note

Gross Margin
Shionogi & Co Ltd

85.7%
Current
85%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
85.7%
=
Gross Profit
358.7B
/
Revenue
418.5B

Gross Margin Across Competitors

Country JP
Market Cap 1.9T JPY
Gross Margin
86%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.1B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 348B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 150.1B USD
Gross Margin
71%
No Stocks Found

Shionogi & Co Ltd
Glance View

Market Cap
1.9T JPY
Industry
Pharmaceuticals

In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.

Intrinsic Value
2 179.09 JPY
Overvaluation 1%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
85.7%
=
Gross Profit
358.7B
/
Revenue
418.5B
What is the Gross Margin of Shionogi & Co Ltd?

Based on Shionogi & Co Ltd's most recent financial statements, the company has Gross Margin of 85.7%.